The present invention relates to a prodrug comprising at least one cytostatic agent, wherein said prodrug is cleavable by prostate-specific antigen (PSA), a process for preparing said prodrug and a pharmaceutical composition containing said prodrug in a pharmaceutically effective amount, for use in the treatment of cancer.
本发明涉及一种前药,包含至少一种细胞增殖
抑制剂,该前药可被前列腺特异性抗原(P
SA)
水解,制备该前药的方法以及含有该前药的药物组合物,用于治疗癌症的药物组合物中含有有效药量的该前药。